Listed by the USPTO as ARCORIA, PAUL JOSEPH
Tech Center 1600 • Art Units: 1621 1623 1629
This examiner grants 100% of resolved cases
ARCORIA, PAUL JOSEPH examines in tech center 1600 and art unit 1621. The profile contains 1 resolved case, with an allowance rate of 100.0% and a median of 810 days to allowance. Interview lift is 0.0%, so the recorded case provides no positive or negative interview association.
The leading companies are Novo Nordisk A/S, Ventus Therapeutics U S Inc., and Mayo Foundation for Medical Education and Research. The leading firms are GOODWIN PROCTER LLP, MH2 TECHNOLOGY LAW GROUP, LLP, and COOLEY LLP. Because the profile contains 1 resolved case, its outcome measures are highly limited as a predictive reference. The company and firm mix identifies the recorded prosecution participants, while the 810-day median provides the available timing context.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18839945 | METHODS FOR TREATING SUBJECTS WITH ABDOMINAL OBESITY HYPERTRIGLYCERIDEMIA AND/OR IMPAIRED GLUCOSE | Non-Final OA | NOVO NORDISK A/S |
| 18837928 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Non-Final OA | Novo Nordisk A/S |
| 18631941 | SYNERGISTIC DRUG COMBINATIONS TO TREAT CANCER | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18281826 | CORE-SHELL DYE, NEAR-INFRARED ABSORBING COMPOSITION INCLUDING THE SAME, AND NEAR-INFRARED ABSORBING FILM | Non-Final OA | SAMSUNG SDI CO., LTD. |
| 18543287 | COMPOSITIONS CONTAINING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE AND AT LEAST ONE BOOSTER | Non-Final OA | L'OREAL |
| 18846183 | TREATMENT OF BREAST CANCER WITH AMCENESTRANT | Non-Final OA | SANOFI |
| 18849105 | DRUG FOR TREATING OR PREVENTING CHARCOT-MARIE-TOOTH DISEASE | Non-Final OA | Kyoto University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy100.0% of resolved applications examined by Paul Joseph Arcoria were allowed (1 resolved cases), compared with 46.0% across Art Unit 1621 over the last five years.
This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Paul Joseph Arcoria took 810 days on average from filing to allowance.
Paul Joseph Arcoria examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
